PCU
HZNP

Palliser Capital (UK)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Palliser Capital (UK)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-79,460
Closed -$8.17M – 9
2023
Q2 		$8.17M Sell
79,460
-4,067
-5% -$429K 8.24% 6
2023
Q1 		$9.12M Buy
+83,527
New +$9.23M 10.32% 5

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Palliser Capital (UK)'s HZNP Position: Q3 2023 in Review

Palliser Capital (UK) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 79,460 shares — an estimated $8.17M sold.

Palliser Capital (UK) first reported a position in HZNP in Q1 2023 and held it in 2 quarters. The position peaked at $9.12M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Palliser Capital (UK) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Palliser Capital (UK) sold 79,460 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $8.17M.
  • Palliser Capital (UK) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 2 quarters.
  • Palliser Capital (UK)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.12M in Q1 2023.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Palliser Capital (UK)'s 13F filing for Q3 2023, filed 11 Oct 2023.